Search

Your search keyword '"Manikowski, Jesse J."' showing total 10 results
Start Over Author "Manikowski, Jesse J."
10 results on '"Manikowski, Jesse J."'

5. Discovery of [11C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR2 Negative Allosteric Modulators.

Author

Perkins, James J., McQuade, Paul, Bungard, Christopher J., Diamond, Tracy L., Gantert, Liza T., Gotter, Anthony L., Hanney, Barbara, Hills, Ivory D., Hurzy, Danielle M., Joshi, Aniket, Kern, Jonathan T., Schlegel, Kelly-Ann S., Manikowski, Jesse J., Meng, Zhaoyang, O'Brien, Julie A., Roecker, Anthony J., Smith, Sean M., Uslaner, Jason M., Hostetler, Eric, and Meissner, Robert S.

Published
2023
Full Text
View/download PDF

7. Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors

Author

Bungard, Christopher J., primary, Williams, Peter D., additional, Schulz, Jurgen, additional, Wiscount, Catherine M., additional, Holloway, M. Katharine, additional, Loughran, H. Marie, additional, Manikowski, Jesse J., additional, Su, Hua-Poo, additional, Bennett, David J., additional, Chang, Lehua, additional, Chu, Xin-Jie, additional, Crespo, Alejandro, additional, Dwyer, Michael P., additional, Keertikar, Kartik, additional, Morriello, Gregori J., additional, Stamford, Andrew W., additional, Waddell, Sherman T., additional, Zhong, Bin, additional, Hu, Bin, additional, Ji, Tao, additional, Diamond, Tracy L., additional, Bahnck-Teets, Carolyn, additional, Carroll, Steven S., additional, Fay, John F., additional, Min, Xu, additional, Morris, William, additional, Ballard, Jeanine E., additional, Miller, Michael D., additional, and McCauley, John A., additional

Published
2017
Full Text
View/download PDF

8. Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group

Author

Bungard, Christopher J., primary, Williams, Peter D., additional, Ballard, Jeanine E., additional, Bennett, David J., additional, Beaulieu, Christian, additional, Bahnck-Teets, Carolyn, additional, Carroll, Steve S., additional, Chang, Ronald K., additional, Dubost, David C., additional, Fay, John F., additional, Diamond, Tracy L., additional, Greshock, Thomas J., additional, Hao, Li, additional, Holloway, M. Katharine, additional, Felock, Peter J., additional, Gesell, Jennifer J., additional, Su, Hua-Poo, additional, Manikowski, Jesse J., additional, McKay, Daniel J., additional, Miller, Mike, additional, Min, Xu, additional, Molinaro, Carmela, additional, Moradei, Oscar M., additional, Nantermet, Philippe G., additional, Nadeau, Christian, additional, Sanchez, Rosa I., additional, Satyanarayana, Tummanapalli, additional, Shipe, William D., additional, Singh, Sanjay K., additional, Truong, Vouy Linh, additional, Vijayasaradhi, Sivalenka, additional, Wiscount, Catherine M., additional, Vacca, Joseph P., additional, Crane, Sheldon N., additional, and McCauley, John A., additional

Published
2016
Full Text
View/download PDF

9. Discovery of [ 11 C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR 2 Negative Allosteric Modulators.

Author

Perkins JJ, McQuade P, Bungard CJ, Diamond TL, Gantert LT, Gotter AL, Hanney B, Hills ID, Hurzy DM, Joshi A, Kern JT, Schlegel KS, Manikowski JJ, Meng Z, O'Brien JA, Roecker AJ, Smith SM, Uslaner JM, Hostetler E, and Meissner RS

Abstract

Modification of potent, selective metabotropic glutamate receptor 2 negative allosteric modulator (mGluR 2 NAM) led to a series of analogues with excellent binding affinity, lipophilicity, and suitable physicochemical properties for a PET tracer with convenient chemical handles for incorporation of a 11 C or 18 F radiolabel. [ 11 C]MK-8056 was synthesized and evaluated in vivo and demonstrated appropriate affinity, selectivity, and physicochemical properties to be used as a positron emission tomography tracer for mGluR 2 ., Competing Interests: The authors declare no competing financial interest., (© 2023 American Chemical Society.)

Published
2023
Full Text
View/download PDF

10. PA- and NP-led Ommaya clinics to manage leptomeningeal carcinomatosis.

Author

Leese EN, Weeder JL, Manikowski JJ, DeLaRue AM, Conger AR, Mahadevan A, Vogel VG, Mongelluzzo GJ, and Gatson NTN

Subjects
Delivery of Health Care, Humans, Retrospective Studies, Meningeal Carcinomatosis drug therapy, Nurse Practitioners, Physician Assistants
Abstract

Objectives: Physician assistants (PAs) and NPs are essential to quality care delivery. The need to demonstrate value and optimize PA and NP roles in neurology subspecialty clinics is unmet. We outline the development of a PA- and NP-led neuro-oncology procedural clinic and provide metrics to support the institutional and clinician value added., Methods: We designed a PA- and NP-led Geisinger Ommaya Clinic (GOC) to manage leptomeningeal carcinomatosis (LMC) with defined clinician roles and the GOC treatment protocol. A retrospective review of 135 patients (2012-2019) compared survival outcomes for patients treated on the protocol compared with those treated off the protocol., Results: Centralized care in the GOCs minimized shared physician encounters and improved PA and NP autonomy and utility. LMC therapy as part of the GOC protocol improved care continuity and survival outcomes., Conclusions: PA- and NP-led procedural clinics optimize use of these clinicians and open physician availability for nonprocedural duties. This research highlights the institutional patient and financial benefit while demonstrating the operational and leadership growth potential for PAs and NPs., (Copyright © 2021 American Academy of Physician Assistants.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results